Skip to Main Content

Cambridge, Mass.-based startup Glympse Bio has raised more than $45 million for its nanoparticle-based biosensors, and it’s hoping the alternative to traditional biopsies can help drug developers test whether their own medicines are actually treating a patient’s condition.

The company’s first biosensors will be tested in some of Gilead’s clinical trials for people with non-alcoholic steatohepatitis, the fatty liver disease known as NASH that is the target of many new experimental treatments.


Glympse is clearly hoping it can follow in the footsteps of Foundation Medicine, a buzzy company that sells blood tests to help people with cancer determine which drugs might be particularly effective. Notably, Glympse’s new investors include Steven Kafka, a former Foundation Medicine executive who is now an investor at Section 32. Its other backers include Temasek, New Leaf Venture Partners, and ARCH Venture Partners.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!